JP2020532535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532535A5 JP2020532535A5 JP2020512443A JP2020512443A JP2020532535A5 JP 2020532535 A5 JP2020532535 A5 JP 2020532535A5 JP 2020512443 A JP2020512443 A JP 2020512443A JP 2020512443 A JP2020512443 A JP 2020512443A JP 2020532535 A5 JP2020532535 A5 JP 2020532535A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- sepiapterin
- composition according
- crystal
- tetrahydrobiopterin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023088749A JP2023116556A (ja) | 2017-09-01 | 2023-05-30 | セピアプテリンを含む医薬組成物及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762553603P | 2017-09-01 | 2017-09-01 | |
| US62/553,603 | 2017-09-01 | ||
| US201862678069P | 2018-05-30 | 2018-05-30 | |
| US62/678,069 | 2018-05-30 | ||
| PCT/US2018/049359 WO2019046849A1 (en) | 2017-09-01 | 2018-09-04 | PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023088749A Division JP2023116556A (ja) | 2017-09-01 | 2023-05-30 | セピアプテリンを含む医薬組成物及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020532535A JP2020532535A (ja) | 2020-11-12 |
| JP2020532535A5 true JP2020532535A5 (enExample) | 2021-10-14 |
| JP7811085B2 JP7811085B2 (ja) | 2026-02-04 |
Family
ID=65526057
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020512443A Active JP7811085B2 (ja) | 2017-09-01 | 2018-09-04 | セピアプテリンを含む医薬組成物及びその使用 |
| JP2023088749A Pending JP2023116556A (ja) | 2017-09-01 | 2023-05-30 | セピアプテリンを含む医薬組成物及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023088749A Pending JP2023116556A (ja) | 2017-09-01 | 2023-05-30 | セピアプテリンを含む医薬組成物及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11752154B2 (enExample) |
| EP (1) | EP3675863A4 (enExample) |
| JP (2) | JP7811085B2 (enExample) |
| CN (1) | CN111491635A (enExample) |
| CA (1) | CA3073957A1 (enExample) |
| MX (1) | MX2020002271A (enExample) |
| WO (1) | WO2019046849A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5066756B2 (ja) | 2010-04-22 | 2012-11-07 | 学校法人日本大学 | 脳機能障害予防・改善用の薬剤及び飲食物 |
| CN110312721A (zh) | 2016-11-29 | 2019-10-08 | 显莎制药公司 | 墨蝶呤的多晶型物 |
| WO2018102315A1 (en) | 2016-11-29 | 2018-06-07 | Censa Pharmaceuticals Inc. | Polymoprhs of sepiapterin and salts thereof |
| MX2020002271A (es) | 2017-09-01 | 2020-10-05 | Ptc Therapeutics Mp Inc | Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas. |
| JP7778477B2 (ja) | 2018-05-30 | 2025-12-02 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンの薬学的に許容される塩 |
| CA3102105A1 (en) | 2018-05-30 | 2019-12-05 | Ptc Therapeutics Mp, Inc. | Compositions and methods for increasing tetrahydrobiopterin plasma exposure |
| JP7502197B2 (ja) | 2018-05-30 | 2024-06-18 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリン血漿曝露を増加させるための方法 |
| LT4009978T (lt) | 2019-08-05 | 2024-11-25 | Ptc Therapeutics Mp, Inc. | Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui |
| IL291565B1 (en) | 2019-09-25 | 2026-04-01 | Ptc Therapeutics Inc | Method for treating phenylalanine irregularity |
| CA3165636A1 (en) | 2020-01-24 | 2021-07-29 | Neil Smith | Methods for treating parkinson's disease with sepiapterin |
| WO2021168206A1 (en) * | 2020-02-19 | 2021-08-26 | Musc Foundation For Research Development | L-sepiapterin and methods of use for treating diseases and disorders |
| US12691119B2 (en) | 2021-02-09 | 2026-07-28 | Ptc Therapeutics Mp, Inc. | Methods for treating covid-19 with sepiapterin |
| IL305037A (en) | 2021-02-09 | 2023-10-01 | Ptc Therapeutics Mp Inc | Methods of treating glioblastomas with spiafatrin |
| AR127191A1 (es) | 2021-09-29 | 2023-12-27 | Ptc Therapeutics Inc | Composición farmacéutica de sepiapterina |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5925323A (ja) | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
| US5753656A (en) | 1994-08-05 | 1998-05-19 | Suntory Limited | Method for treating spinocerebellar degeneration |
| WO1997007236A1 (en) | 1995-08-18 | 1997-02-27 | Landry Donald W | Detection of organic compounds through regulation of antibody-catalyzed reactions |
| US8188043B2 (en) * | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
| GB0116620D0 (en) | 2001-07-07 | 2001-08-29 | Astrazeneca Ab | Formulation |
| ITMI20011732A1 (it) | 2001-08-07 | 2003-02-07 | Indena Spa | Composizioni farmaceutiche e/o cosmetiche orali per il trattamento e la prevenzione di disturbi del cuoio capelluto |
| FR2859996B1 (fr) | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
| JP2007509909A (ja) | 2003-10-31 | 2007-04-19 | アルタナ ファルマ アクチエンゲゼルシャフト | 呼吸器疾患の治療のためのｂｈ４の使用 |
| CA2545968C (en) | 2003-11-17 | 2010-03-09 | Merck Eprova Ag | Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride |
| PT3138566T (pt) | 2003-11-17 | 2022-02-02 | Biomarin Pharm Inc | Tratamento de fenilcetonúria com bh4 |
| JP5184783B2 (ja) | 2003-11-17 | 2013-04-17 | バイオマリン ファーマシューティカル インコーポレイテッド | テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法 |
| CN101132776A (zh) | 2004-11-17 | 2008-02-27 | 生物马林药物股份有限公司 | 稳定的四氢生物喋呤片剂制剂 |
| US20100130500A1 (en) | 2004-12-08 | 2010-05-27 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of pulmonary hypertension of the newborn |
| WO2006118322A1 (en) | 2005-04-28 | 2006-11-09 | Shiratori Pharmaceutical Co., Ltd. | Method for producing hydrazone derivatives |
| US20080075666A1 (en) * | 2006-08-25 | 2008-03-27 | Dudley Samuel C Jr | Methods and compositions for treating diastolic dysfunction |
| KR20160065998A (ko) | 2007-04-11 | 2016-06-09 | 바이오마린 파머수티컬 인크. | 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법 |
| LT2262790T (lt) | 2008-03-10 | 2017-08-25 | Takeda Pharmaceutical Company Limited | Benzimidazolo junginio kristalas |
| WO2010017570A2 (de) * | 2008-08-12 | 2010-02-18 | Orpha Swiss Gmbh | Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin |
| EP2382216A1 (en) | 2008-12-23 | 2011-11-02 | Boehringer Ingelheim International GmbH | Salt forms of organic compound |
| JP2012533633A (ja) | 2009-07-20 | 2012-12-27 | ベテゲン・エルエルシー | 経口投与のための安定な薬学的オメプラゾール製剤 |
| IN2012DN01453A (enExample) | 2009-08-20 | 2015-06-05 | Novartis Ag | |
| JP5066756B2 (ja) | 2010-04-22 | 2012-11-07 | 学校法人日本大学 | 脳機能障害予防・改善用の薬剤及び飲食物 |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| CA2828685C (en) | 2011-03-01 | 2018-05-29 | Rubicon Research Private Limited | Stable compositions of tetrahydrobiopterin |
| US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
| JP6084967B2 (ja) * | 2012-05-07 | 2017-02-22 | 白鳥製薬株式会社 | セピアプテリン及びテトラヒドロラクトイルプテリンの製造法 |
| ES2586945T3 (es) * | 2014-03-31 | 2016-10-19 | Vasopharm Gmbh | Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de dichas composiciones |
| AU2015260837B2 (en) | 2014-05-12 | 2019-02-28 | Alfasigma S.P.A. | New solvated crystal form of rifaximin, production, compositions and uses thereof |
| IL301320B2 (en) | 2014-12-02 | 2024-11-01 | Minerva Neurosciences Inc | Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia |
| JP2018531964A (ja) | 2015-10-27 | 2018-11-01 | インシス・ディベロップメント・カンパニー・インコーポレイテッド | 液体ブプレノルフィン製剤 |
| JP6967334B2 (ja) | 2015-12-21 | 2021-11-17 | 備前化成株式会社 | 高度不飽和脂肪酸のエステルを含む組成物 |
| WO2017218421A1 (en) | 2016-06-13 | 2017-12-21 | Meharry Medical College | Modulation of the nitric oxide synthase pathway for oral health |
| WO2018019931A1 (en) * | 2016-07-29 | 2018-02-01 | Dipharma S.A. | Pharmaceutical composition kit comprising sapropterin dihydrochloride |
| CN110312721A (zh) | 2016-11-29 | 2019-10-08 | 显莎制药公司 | 墨蝶呤的多晶型物 |
| WO2018102315A1 (en) * | 2016-11-29 | 2018-06-07 | Censa Pharmaceuticals Inc. | Polymoprhs of sepiapterin and salts thereof |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| MX2020002271A (es) | 2017-09-01 | 2020-10-05 | Ptc Therapeutics Mp Inc | Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas. |
| CA3102105A1 (en) | 2018-05-30 | 2019-12-05 | Ptc Therapeutics Mp, Inc. | Compositions and methods for increasing tetrahydrobiopterin plasma exposure |
| JP7778477B2 (ja) | 2018-05-30 | 2025-12-02 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンの薬学的に許容される塩 |
| JP7502197B2 (ja) | 2018-05-30 | 2024-06-18 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリン血漿曝露を増加させるための方法 |
| LT4009978T (lt) | 2019-08-05 | 2024-11-25 | Ptc Therapeutics Mp, Inc. | Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui |
| IL291565B1 (en) | 2019-09-25 | 2026-04-01 | Ptc Therapeutics Inc | Method for treating phenylalanine irregularity |
-
2018
- 2018-09-04 MX MX2020002271A patent/MX2020002271A/es unknown
- 2018-09-04 EP EP18850633.1A patent/EP3675863A4/en active Pending
- 2018-09-04 CA CA3073957A patent/CA3073957A1/en active Pending
- 2018-09-04 CN CN201880070952.7A patent/CN111491635A/zh active Pending
- 2018-09-04 WO PCT/US2018/049359 patent/WO2019046849A1/en not_active Ceased
- 2018-09-04 JP JP2020512443A patent/JP7811085B2/ja active Active
-
2019
- 2019-10-31 US US16/670,362 patent/US11752154B2/en active Active
-
2023
- 2023-05-30 JP JP2023088749A patent/JP2023116556A/ja active Pending
- 2023-08-18 US US18/235,486 patent/US12213982B2/en active Active
-
2024
- 2024-12-20 US US18/990,477 patent/US20250195526A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274488B2 (en) | Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | |
| JP2021527031A5 (enExample) | ||
| JP2021505575A5 (enExample) | ||
| JP2024063143A5 (enExample) | ||
| JP2015509972A5 (enExample) | ||
| JP2009506014A5 (enExample) | ||
| HRP20240033T1 (hr) | Formulacija koja sadrži inhibitor mek | |
| AU2012335981C1 (en) | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | |
| JP2017537899A5 (enExample) | ||
| SI2760821T1 (en) | A salt salt of an anti-inflammatory substituted cyclobutenedione compound | |
| EA032421B1 (ru) | Составы (s)-3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона | |
| HRP20180018T1 (hr) | Kombinacija agonista receptora 5-ht 4 i inhibitora acetilkolinesteraze za liječenje kognitivnog poremećaja | |
| JP2011530540A5 (enExample) | ||
| AU2012274160A2 (en) | Deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo- N-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide | |
| JP2016503010A5 (enExample) | ||
| JP2016006070A (ja) | Ｈｄａｃ阻害剤と代謝拮抗剤の組み合わせ | |
| JPWO2009038112A1 (ja) | Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤 | |
| HRP20160545T1 (hr) | Inhibitor fosfoinozitid 3-kinaze sa dijelom koji veže cink | |
| MX2020012978A (es) | Sales de sepiapterina farmacéuticamente aceptables. | |
| RU2015140611A (ru) | Коньюгат бензофуранона и индола или азаиндола, его получение и применения | |
| EA039121B1 (ru) | ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2 | |
| WO2017041680A1 (zh) | 一种沃替西汀或其盐的药用组合物及其制备方法 | |
| JP2015120758A5 (enExample) | ||
| AU2019338483B2 (en) | Combination therapy for the treatment of prostate cancer | |
| CN106551946B (zh) | 一种含三氟胸苷和盐酸替比嘧啶的药物组合物及制备方法 |